{"id":82135,"date":"2023-02-10T10:14:28","date_gmt":"2023-02-10T09:14:28","guid":{"rendered":"https:\/\/lightweb.dev\/s\/key2compliance\/?p=82135"},"modified":"2023-02-10T10:56:36","modified_gmt":"2023-02-10T09:56:36","slug":"atrogi-announces-first-patient-treated-with-its-atr-258-b2-adrenoceptor-agonist","status":"publish","type":"post","link":"https:\/\/lightweb.dev\/s\/key2compliance\/news\/atrogi-announces-first-patient-treated-with-its-atr-258-b2-adrenoceptor-agonist\/","title":{"rendered":"Atrogi announces first patient treated with its ATR-258 \u00df2 adrenoceptor agonist"},"content":{"rendered":"<p>Key2Compliance are happy to celebrate that our client, Atrogi, has announced first patient treated with its ATR-258 \u00df<sub>2<\/sub>-adrenoceptor agonist in their ongoing phase 1 study for the treatment of Type 2 Diabetes.<\/p>\n<p><a href=\"https:\/\/atrogi.com\/\">Atrogi<\/a>\u00a0is an early-stage Swedish pharma company developing a novel solution for the treatment of Type 2 Diabetes. The trial is expected to be completed in mid-2023.<\/p>\n<p>Key2Compliance supports the Atrogi team with clinical project management of the study, that is conducted in Germany, and we are thrilled to be part of this very interesting study.<\/p>\n<p>Read the press release from Atrogi <a href=\"https:\/\/news.cision.com\/let-em-know-ab\/r\/atrogi-announces-first-patient-treated-with-its-atr-258-ss-2--adrenoceptor-agonist-in-a-phase-i-clin,c3702805\">here<\/a>.<\/p>\n<p><strong>About Atrogi<\/strong><strong><br \/>\n<\/strong>Atrogi, a Swedish pharmaceutical R&amp;D company, develops a revolutionizing solution for the treatment of type 2 diabetes aimed at the global market. Atrogi was founded in 2013 based on results from professor Tore Bengtsson. Please visit:\u00a0<a href=\"http:\/\/www.atrogi.com\/\">www.atrogi.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key2Compliance are happy to celebrate that our client, Atrogi, has announced first patient treated with its ATR-258 \u00df2-adrenoceptor agonist in their ongoing phase 1 study for the treatment of Type 2 Diabetes. Atrogi\u00a0is an early-stage Swedish pharma company developing a novel solution for the treatment of Type 2 Diabetes. The trial is expected to be [&hellip;]<\/p>\n","protected":false},"author":18,"featured_media":82136,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wds_primary_category":21,"footnotes":""},"categories":[21],"tags":[],"blog-subject":[],"class_list":["post-82135","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts\/82135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/comments?post=82135"}],"version-history":[{"count":0,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts\/82135\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/media\/82136"}],"wp:attachment":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/media?parent=82135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/categories?post=82135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/tags?post=82135"},{"taxonomy":"blog-subject","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/blog-subject?post=82135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}